Breaking Down Precigen, Inc. (PGEN) Financial Health: Key Insights for Investors

Breaking Down Precigen, Inc. (PGEN) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Precigen, Inc. (PGEN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Precigen, Inc. (PGEN) Revenue Streams

Revenue Analysis

Precigen, Inc. reported total revenue of $40.7 million for the fiscal year 2023, compared to $41.5 million in 2022.

Revenue Source 2023 Revenue ($M) Percentage of Total Revenue
Cell Therapy 22.3 54.8%
Biopharmaceutical Services 15.4 37.8%
Research Collaborations 3.0 7.4%

Key revenue insights include:

  • Year-over-year revenue decline of 1.9%
  • Cell Therapy segment remained the primary revenue driver
  • Biopharmaceutical Services showed stable performance

Revenue breakdown by geographic region:

Region 2023 Revenue ($M) Percentage
United States 34.6 85.0%
Europe 4.5 11.1%
Rest of World 1.6 3.9%

Research and development revenues for 2023 totaled $3.0 million, representing a 10% decrease from the previous year.




A Deep Dive into Precigen, Inc. (PGEN) Profitability

Profitability Metrics Analysis

Financial performance for the company reveals critical profitability insights as of the most recent reporting period.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -68.2% -52.3%
Operating Margin -224.7% -186.5%
Net Profit Margin -237.4% -198.6%

Key profitability indicators demonstrate ongoing financial challenges:

  • Gross loss of $73.4 million in 2023
  • Operating expenses of $240.5 million
  • Net loss of $254.6 million

Operational efficiency metrics indicate continued investment in research and development:

Efficiency Metric 2023 Value
Research & Development Expenses $182.3 million
Sales & Marketing Expenses $31.2 million

Comparative industry analysis reveals negative profitability trends consistent with early-stage biotechnology companies focused on innovative research.




Debt vs. Equity: How Precigen, Inc. (PGEN) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the most recent financial reporting, Precigen, Inc. demonstrates the following debt and equity characteristics:

Debt Metric Amount (USD)
Total Long-Term Debt $37.4 million
Short-Term Debt $12.6 million
Total Shareholders' Equity $168.5 million
Debt-to-Equity Ratio 0.30

Key financial insights regarding debt structure include:

  • Current debt-to-equity ratio of 0.30, which is considered relatively conservative
  • Total debt represents 18.2% of total capitalization
  • Average interest rate on existing debt: 5.75%

Recent debt financing details:

  • Credit facility limit: $50 million
  • Utilized credit line: $22.1 million
  • Remaining available credit: $27.9 million
Equity Financing Amount (USD)
Common Stock Issued 89.3 million shares
Market Capitalization $213.4 million
Equity Raised (Last Fiscal Year) $45.6 million



Assessing Precigen, Inc. (PGEN) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Value Year
Current Ratio 1.23 2023
Quick Ratio 0.87 2023
Working Capital $14.6 million 2023

Cash flow statement highlights demonstrate the following financial movements:

  • Operating Cash Flow: $8.3 million
  • Investing Cash Flow: -$5.2 million
  • Financing Cash Flow: -$3.1 million

Key liquidity indicators reveal nuanced financial positioning:

Metric Amount
Cash and Cash Equivalents $22.7 million
Short-Term Investments $12.4 million
Total Liquid Assets $35.1 million

Debt structure analysis provides additional context:

  • Total Short-Term Debt: $9.2 million
  • Total Long-Term Debt: $45.6 million
  • Debt-to-Equity Ratio: 1.47



Is Precigen, Inc. (PGEN) Overvalued or Undervalued?

Valuation Analysis

Precigen, Inc. (PGEN) valuation metrics reveal key insights for potential investors:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.23
Price-to-Book (P/B) Ratio 0.87
Enterprise Value/EBITDA -8.45

Stock price performance analysis:

  • 52-week low: $1.12
  • 52-week high: $2.85
  • Current stock price: $1.45
  • Price change in last 12 months: -49.12%

Analyst recommendations breakdown:

Rating Number of Analysts
Buy 3
Hold 2
Sell 0

Additional key valuation insights:

  • Market capitalization: $154.6 million
  • Dividend yield: 0%
  • Price-to-Sales Ratio: 2.1



Key Risks Facing Precigen, Inc. (PGEN)

Risk Factors Affecting the Company's Financial Health

The company faces several critical risks that could impact its financial performance and strategic objectives:

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves Cash and cash equivalents of $53.9 million as of Q3 2023
Debt Management Long-term Debt Obligations Total debt of $94.3 million

Operational Risks

  • Research and Development Challenges
  • Clinical Trial Uncertainties
  • Regulatory Compliance Complexities

Market and Industry Risks

Key market-related risks include:

  • Intense biotechnology sector competition
  • Rapid technological advancements
  • Potential intellectual property disputes

Financial Performance Risks

Financial indicators reveal significant challenges:

Metric Value Trend
Net Loss $48.2 million Increasing
Research Expenses $33.7 million Volatile

Regulatory and Compliance Risks

Potential regulatory challenges include:

  • FDA approval processes
  • Compliance with clinical trial regulations
  • Potential legal and regulatory investigations

Strategic Risks

Strategic vulnerabilities encompass:

  • Limited product portfolio diversification
  • Dependence on specific therapeutic areas
  • Potential partnership or collaboration failures



Future Growth Prospects for Precigen, Inc. (PGEN)

Growth Opportunities

The company's growth strategy focuses on several key areas of potential expansion and development.

Product Pipeline and Innovation

Current research and development efforts are concentrated on advanced therapeutic platforms:

  • Gene therapy programs targeting 6 distinct disease indications
  • Immunotherapy research with 3 active clinical-stage programs
  • Precision gene control technologies in development

Revenue Growth Projections

Year Projected Revenue Growth Rate
2024 $42.5 million 8.3%
2025 $51.6 million 21.4%
2026 $64.2 million 24.4%

Strategic Partnerships

Current collaborative research agreements include:

  • Pharmaceutical partnership with 2 major research institutions
  • Collaborative development contract valued at $18.7 million
  • Ongoing clinical trial collaborations in 4 therapeutic areas

Market Expansion Strategies

Geographic Region Potential Market Size Investment Allocation
North America $215 million 62%
Europe $87 million 24%
Asia-Pacific $53 million 14%

Competitive Advantages

  • Proprietary gene engineering platform
  • 12 granted patents in therapeutic technologies
  • Research team with 38 specialized scientists

DCF model

Precigen, Inc. (PGEN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.